Novavax is entering the New Year with final plans for an emergency use authorization application filing to the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine, NVX-CoV2373. On Friday, Maryland-based Novavax announced it completed the submission of its final data package to the FDA. Information contained includes the complete …